Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02964585 · ClinicalTrials.gov registry record · Phase 4
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
A Phase 4 study, sponsored by George Washington University.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT02964585 is a Phase 4 study that has completed, run by George Washington University. The registered enrollment target is 34 participants.
The verdict
NCT02964585, a Phase 4 study, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
The investigators hypothesize that Cana may be able to improve number and function of CD34+ endothelial progenitor cells. The investigators also propose that this expected cardiovascular benefit is independent of HbA1C reduction. Subjects will begin taking 100 mg of Cana or placebo after initial 4 weeks. Subjects will be withdrawn from the study if the medication or placebo is not tolerated.
Interventions
- DRUG Placebo
- DRUG Canagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-11 |
| Est. Completion | 2020-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02964585
The ClinicalTrials.gov registry entry for NCT02964585 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02964585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02964585 about?
NCT02964585 is a clinical study titled "Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes". The investigators hypothesize that Cana may be able to improve number and function of CD34+ endothelial progenitor cells. The investigators also propose that this expected cardiovascular benefit is independent of HbA1C reduction. Subjects will begin taking 100 mg of Cana or placebo after initial 4 ...
What is the current status of trial NCT02964585?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2016-11. Estimated completion is 2020-09.
What interventions are being tested in trial NCT02964585?
The interventions under investigation include: Placebo (DRUG), Canagliflozin (DRUG).
Who is sponsoring clinical trial NCT02964585?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.